Journal of Thoracic Oncology (JTO), March 2024, Volume 19, Issue 3
Journal | English
Image For Activity Cover
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered
In This Issue
  • Research Watch/News in Brief
  • Tobacco News Update - From the IASLC Tobacco Control Committee
Editorials
  • Invasive Size in Lung Adenocarcinoma—Reproducible Criteria, More Accurate Staging
  • Mismatch Repair Deficiency in Lung Tumors: Adding a New Layer of Complexity on Pie Slices
  • Anti–Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1 Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary
  • MUC1-C: The Occam Razor of Osimertinib Resistance?
  • Considerations for Enhancing Lung Cancer Risk Prediction and Screening in Asian Populations
Controversies in Thoracic Oncology
  • Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFRD NSCLC 
  • Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFRD NSCLC
Editorial - Lung Cancer Worldwide
  • Lung Cancer in Switzerland
Review Articles
  • Immune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges
Original Articles
  • Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation
  • Clinical Significance of the Proposed Pathologic Criteria for Invasion by the International Association for the Study of Lung Cancer in Resected Nonmucinous Lung Adenocarcinoma
  • MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC
  • Lung Cancer Risk Prediction Models for Asian Ever-Smokers
  • A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC
  • Prospective Cohort Study to Compare Long-Term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a–b; £20 mm) NSCLC Treated by Stereotactic Body Radiation Therapy and Surgery
  • Five-Year Survival Outcomes After Carbon-Ion Radiotherapy for Operable Stage I NSCLC: A Japanese National Registry Study (J-CROS-LUNG)
Brief Report
  • Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC 
Letters to the Editor
  • Survival and Prognosis After Carbon-Ion Radiotherapy in Patients With NSCLC 
  • Response to Letter to the Editor
  • How Does Rheumatoid Arthritis Increase the Risk of Lung Cancer?
  • Response to Letter to the Editor
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance.

Authors are also welcome to submit to the journal's open access companion title, JTO Clinical and Research Reports, which welcomes a range of manuscripts from subset analyses of published trials to high-quality case reports
Powered By